Tate & Lyle PLC (OTCMKTS:TATYY) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a report released on Saturday. The firm currently has a $39.00 target price on the stock. Zacks Investment Research’s price target would suggest a potential upside of 11.75% from the company’s previous close.

According to Zacks, “Tate & Lyle Ventures and Agri Investment Fund have co-led a 3.5m investment into Fugeia, a newly formed functional food technology business with a focus on gut health. “

Several other analysts have also recently issued reports on the company. Davy Research reiterated a “neutral” rating on shares of Tate & Lyle PLC in a research note on Thursday, November 3rd. Societe Generale cut Tate & Lyle PLC from a “buy” rating to a “hold” rating in a research note on Monday, November 7th. BNP Paribas cut Tate & Lyle PLC from a “neutral” rating to an “underperform” rating in a research note on Wednesday. Finally, Citigroup Inc. restated a “neutral” rating on shares of Tate & Lyle PLC in a research note on Thursday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $39.00.

Analyst Recommendations for Tate & Lyle PLC (OTCMKTS:TATYY)

About Tate & Lyle PLC

Tate & Lyle PLC provides ingredients and solutions to the food, beverage and other industries. The Company operates through two business segments: Speciality Food Ingredients, which offers products, such as sweeteners, texturants, health and wellness, and food systems, and Bulk Ingredients segment, which offers products, such as liquid sweeteners, industrial starches, citric acid, bio-fuels and animal feed.

Receive News & Stock Ratings for Tate & Lyle PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tate & Lyle PLC and related stocks with our FREE daily email newsletter.